| Followers | 9 |
| Posts | 3233 |
| Boards Moderated | 0 |
| Alias Born | 04/21/2025 |
Tuesday, September 09, 2025 3:41:07 PM
There is ZERO clinical evidence of that ridiculous statement.
Orange juice has no side effects either! While PFS and OS are both important, changed endpoints, crossover and post hoc external controls render a trial null and void. Period, EOM.
That is exactly what NWBO did, and why the FDA sent them packing!
Randomized double blind trials with PFS as the main endpoint with OS follow up as 2nd endpoint are the GOLD STANDARD.
Why PFS is the Gold StandardDirect Measure of Treatment Effect: PFS evaluates how well a treatment delays disease progression, reflecting the drug’s ability to control tumor growth.
Faster Results: Compared to Overall Survival (OS), PFS provides earlier evidence of efficacy, as progression often occurs before death, allowing trials to conclude more quickly.
Less Confounding: PFS is less influenced by subsequent therapies or crossover treatments compared to OS, which can be affected by post-progression treatments.
Regulatory Acceptance: Regulatory bodies like the FDA and EMA often accept PFS as a primary endpoint for drug approval, especially in diseases where progression is a reliable indicator of clinical benefit (e.g., advanced cancers).
Gary
Orange juice has no side effects either! While PFS and OS are both important, changed endpoints, crossover and post hoc external controls render a trial null and void. Period, EOM.
That is exactly what NWBO did, and why the FDA sent them packing!
Randomized double blind trials with PFS as the main endpoint with OS follow up as 2nd endpoint are the GOLD STANDARD.
Why PFS is the Gold StandardDirect Measure of Treatment Effect: PFS evaluates how well a treatment delays disease progression, reflecting the drug’s ability to control tumor growth.
Faster Results: Compared to Overall Survival (OS), PFS provides earlier evidence of efficacy, as progression often occurs before death, allowing trials to conclude more quickly.
Less Confounding: PFS is less influenced by subsequent therapies or crossover treatments compared to OS, which can be affected by post-progression treatments.
Regulatory Acceptance: Regulatory bodies like the FDA and EMA often accept PFS as a primary endpoint for drug approval, especially in diseases where progression is a reliable indicator of clinical benefit (e.g., advanced cancers).
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
